ReviewiScience2026
Deep brain stimulation mechanisms in comorbid pain and emotional dysregulation from animal models.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep brain stimulation (DBS) is a potent neuromodulatory intervention for chronic pain and comorbid affective disorders. This review synthesizes preclinical evidence detailing the neural circuits and molecular cascades engaged by DBS in models of pain and emotional dysregulation. We delineate how DBS-targeting regions like the prefrontal cortex (PFC), thalamus, and nucleus accumbens (NAc) recruit the prefrontal-midbrain-spinal axis to facilitate endogenous opioid release and modulate neurotransmission, thereby attenuating nociception. Concurrently, stimulating the ventromedial PFC (vmPFC) or lateral habenula (LHb) ameliorates affective deficits by restoring serotonergic (5-HT) and dopaminergic (DA) tone and stabilizing circuit dynamics. By mapping these convergent and divergent mechanisms, we highlight how DBS fine-tunes reward, anti-reward, and descending antinociceptive pathways. This mechanism-based framework outlines a translational roadmap for personalized neuromodulation, guiding symptom-specific target selection and the development of biomarker-driven, closed-loop DBS systems to concurrently treat pain and affective pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.